SRPT - Sarepta Therapeutics, Inc.
IEX Last Trade
122.08
-2.970 -2.433%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:00:34 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
35.29%
PREVIOUS CLOSE
CHG
CHG%
$125.05
-2.97
-2.38%
Fundamental analysis
28%
Profitability
18%
Dept financing
20%
Liquidity
70%
Performance
31%
Performance
5 Days
2.46%
1 Month
6.32%
3 Months
-2.18%
6 Months
-22.88%
1 Year
28.94%
2 Year
-3.74%
Key data
Stock price
$122.08
DAY RANGE
$121.12 - $125.05
52 WEEK RANGE
$95.00 - $173.00
52 WEEK CHANGE
$25.88
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Douglas S. Ingram
Region: US
Website: sarepta.com
Employees: 840
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sarepta.com
Employees: 840
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.
Recent news